clinical impact of subq daratumumab for multiple myeloma
Published 4 years ago • 69 plays • Length 3:08Download video MP4
Download video MP3
Similar videos
-
1:47
practical management of iv daratumumab in mm
-
3:15
daratumumab for the treatment of patients with multiple myeloma
-
1:48
the impact of cd38-targeted therapy in multiple myeloma
-
15:09
subcutaneous daratumumab — dr. jonathan kaufman | mcrt webcast july 11
-
1:02
dr. shain on subcutaneous therapy for patients with multiple myeloma
-
1:03
promising findings for daratumumab plus vrd in multiple myeloma
-
3:54
vmp daratumumab for high-risk multiple myeloma
-
14:28
all about darzalex (daratumumab)
-
2:07
myeloma: impact of the alcyone trial
-
4:27
exciting subcutaneous formulation approval in mm
-
12:21
elotuzumab and daratumumab in multiple myeloma
-
1:05
dr. harrison on subcutaneous daratumumab and isatuximab in myeloma
-
6:59
teclistamab in combination with sub-q daratumumab and lenalidomide in myeloma pts: majestec-2
-
3:17
ever-expanding indications for daratumumab in mm
-
3:36
results for the combination of selinexor and daratumumab in multiple myeloma
-
2:24
dr sonneveld on the fda approval of subcutaneous daratumumab plus vrd in myeloma
-
4:58
evaluating the impact of daratumumab for the treatment of multiple myeloma according to cytogene...
-
1:23
dr. landgren on using daratumumab for patients with multiple myeloma
-
1:08
an overview of daratumumab monotherapy for heavily treated multiple myeloma